Table 1.
Characteristics of Vaccine Responders and Nonresponders Using the Ortho Clinical Diagnostic Anti-SARS-Cov-2 IGg Immunoassay to Assess Response
| Characteristic | All (N = 55) | Antibody-Positive after First Vaccine (N = 21) | Antibody- Negative after First Vaccine (N = 34) | P Value |
|---|---|---|---|---|
| Age, yr, median (range) | 50 (18-73) | 29 (18-73) | 51 (23-73) | .038* |
| Sex, n (%) Male Female |
34 (61.8) 21 (38.2) |
13 (61.9) 8 (38.1) |
21 (61.8) 13 (38.2) |
.991 |
| Diagnosis, n (%) Acute lymphoblastic leukemia Acute myelogenous leukemia Aplastic anemia Myelodysplastic syndrome Non-Hodgkin lymphoma Hodgkin lymphoma Myelofibrosis |
13 (23.6) 23 (41.8) 2 (3.6) 7 (12.7) 7 (12.7) 2 (3.6) 1 (1.8) |
6 (28.6) 9 (42.9) 2 (9.5) 1 (4.8) 3 (14.2) 0 0 |
7 (20.6) 14 (41.2) 0 6 (17.6) 4 (11.8) 2 (5.9) 1 (2.9) |
.302 |
| Donor type, n (%) Sibling Matched unrelated Umbilical cord Haploidentical |
9 (16.4) 35 (63.6) 7 (12.7) 4 (7.3) |
2 14 3 2 |
7 21 4 2 |
.766 |
| Conditioning, n (%) Full-intensity conditioning Reduced-intensity conditioning |
16 (29.1) 39 (70.9) |
8 (39.1) 13 (61.9) |
8 (23.5) 26 (76.5) |
.248 |
| T cell depletion, n (%) Campath Antithymocyte globulin None |
30 (54.5) 6 (10.9) 19 (34.5) |
11 (52.3) 2 (9.5) 8 (38.1) |
19 (55.9) 4 (11.8) 11 (32.4) |
.899 |
| Acute GVHD, n (%) | 6 | 0 | 6 (17.6) | .072 |
| Chronic GVHD, n (%) | 35 | 11 (52.3) | 24 (70.5) | .173 |
| Immune suppression at vaccination, n (%) On immune suppression No immune suppression |
29 26 |
6 (28.6) 15 (57.7) |
23 (67.6) 11 (42.3) |
.0062 |
| Time to vaccination post-HCT, n (%) 3-6 mo >6 months |
8 47 |
1 (4.7) 20 (95.2) |
7 (20.5) 27 (79.4) |
.136 |
| Time from vaccine to antibody assessment, d, median (range) | 42.1 (14-84) | 35 (14-74) | 46.5 (14-84) | .226 |
| Lymphocyte count at time of vaccination, × 109/L, median | 1.18 | 1.33 | 1.11 | .062 |
| Type of vaccine, n PB AZ |
21 34 |
4 17 |
17 17 |
.021* |
| Rituximab within last 12 mo, n Yes No |
10 45 |
2 19 |
8 26 |
.191 |
GVHD indicates graft-versus-host disease.